Kazia Therapeutics Limited (KZIA)
|Net Income (ttm)||-8.60M|
|Trading Day||January 25|
|Day's Range||10.20 - 10.74|
|52-Week Range||2.56 - 13.47|
Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St ... [Read more...]
|IPO Date |
Jan 6, 1999
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (
|Stock Exchange |
|Ticker Symbol |
In 2020, KZIA's revenue was 1.06 million, a decrease of -32.20% compared to the previous year's 1.57 million. Losses were -12.47 million, 21.4% more than in 2019.
According to one analyst, the rating for KZIA stock is "Buy" and the 12-month stock price forecast is 17.03.